A study of DCR-PHXC for the treatment of primary hyperoxaluria (PH).
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs DCR PHXC (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 17 Aug 2017 According to a Dicerna Pharmaceuticals media release, the company expect to commence human clinical trials in the first quarter of 2018. I have added information to this study only. Please update when more clear information become available.
- 08 May 2017 This trial is expected to begin in the first quarter of 2018, according to a Dicerna Pharmaceuticals media release.
- 22 Nov 2016 New trial record